Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Outgoing OGD Director Outlines Accomplishments During His Tenure

Executive Summary

Gregory Geba highlights the strides the Office of Generic Drugs made in implementing the generic drug user fee program in his resignation announcement.

Advertisement

Related Content

ANDA Pre-Submission Meetings Being Considered By FDA
FDA Generics Director’s Departure Shows Why Chemistry Matters
FDA Generics Director’s Departure Shows Why Chemistry Matters
Hamburg Trumpets Potential Rewards Of Quality Improvement For Generic Industry
GDUFA Self-Identification Woes Can’t Deflate Industry, FDA Enthusiasm
ANDA User Fees Will Fund Public Relations-focused Studies On Palatability Of Generics
FDA Reshuffles Office Of Generic Drugs To Improve Performance

Topics

Advertisement
UsernamePublicRestriction

Register

PS055190

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel